Pharmacologic resistance in colorectal cancer: a review

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

[1]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[2]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[3]  P. Johnston,et al.  Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan , 2004, Clinical Cancer Research.

[4]  P. Jänne,et al.  Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.

[5]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Gamelin,et al.  Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity , 2004, Clinical Cancer Research.

[7]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  E. Van Cutsem,et al.  Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. , 2014, European journal of cancer.

[9]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[10]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[12]  H. Minami,et al.  An overview of the recent progress in irinotecan pharmacogenetics. , 2010, Pharmacogenomics.

[13]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[14]  P. Jänne,et al.  EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[17]  Benjamin Hirschi,et al.  Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells , 2014, Molecular Cancer.

[18]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[19]  Jun Liang,et al.  The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer , 2010, Cancer Chemotherapy and Pharmacology.

[20]  J. Lindebjerg,et al.  Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. , 2006, International journal of oncology.

[21]  D. Gu,et al.  Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A meta-analysis , 2014, Cancer science.

[22]  I. Hyodo,et al.  Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sung Sook Lee,et al.  A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity , 2012, Oncology.

[24]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[25]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[26]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[27]  A. Causse,et al.  New Topoisomerase I mutations are associated with resistance to camptothecin , 2011, Molecular Cancer.

[28]  M. Lucock,et al.  Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. , 2004, Journal of the National Cancer Institute.

[29]  W. Bodmer,et al.  DNA mismatch repair genes and colorectal cancer , 2000, Gut.

[30]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[31]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[32]  U. McDermott,et al.  The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. , 2002, Cancer research.

[33]  R. Crystal,et al.  Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. , 1998, Cancer research.

[34]  A. Bardelli,et al.  Acquired resistance to EGFR‐targeted therapies in colorectal cancer , 2014, Molecular oncology.

[35]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[36]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[37]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[38]  L. Mazzucchelli,et al.  Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.

[39]  A. Zaniboni,et al.  The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. , 2014, Reviews on recent clinical trials.

[40]  S. Howell,et al.  Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin , 2006, Molecular Pharmacology.

[41]  Sabine Tejpar,et al.  Overcoming resistance to antiangiogenic therapies. , 2012, The oncologist.

[42]  Rebecca L. Siegel Mph,et al.  Colorectal cancer statistics, 2014 , 2014 .

[43]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[44]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[45]  A. Longatto-Filho,et al.  Therapy in Colorectal Cancer with Liver Metastasis – A Multidisciplinary Management , 2018 .

[46]  F. Russo,et al.  EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma , 1998 .

[47]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[48]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[49]  Jeffrey S. Morris,et al.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[51]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[53]  S. Groshen,et al.  Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Merlo,et al.  Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation* , 2004, Journal of Biological Chemistry.

[55]  A. Fedier,et al.  The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. , 2003, International journal of oncology.

[56]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[57]  H. Ludwig,et al.  The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer , 1993, Cancer.

[58]  J. S. Macpherson,et al.  Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. , 2002, Biochemical pharmacology.

[59]  Y. Mandel-Gutfreund,et al.  Heterogeneous Nuclear Ribonucleoprotein H1/H2-dependent Unsplicing of Thymidine Phosphorylase Results in Anticancer Drug Resistance , 2010, The Journal of Biological Chemistry.

[60]  P. Rougier,et al.  Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. , 1996, European journal of cancer.

[61]  R. Diasio,et al.  Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Russell S. Thomas,et al.  Systems pharmacology assessment of the 5-fluorouracil pathway. , 2011, Pharmacogenomics.

[63]  M. Ychou,et al.  Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  H. Nielsen,et al.  Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer , 2013, Scandinavian journal of gastroenterology.

[65]  C. Bellan,et al.  Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin , 2010, Anti-cancer drugs.

[66]  C. Behling,et al.  Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. , 2004, Gastroenterology.

[67]  Z. Mo,et al.  XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis , 2013, Cancer Chemotherapy and Pharmacology.

[68]  Franklin Peale,et al.  Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.

[69]  N. Normanno,et al.  HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. , 2011, Cancer discovery.

[70]  R. Roskoski.  ERK1/2 MAP kinases: structure, function, and regulation. , 2012, Pharmacological research.

[71]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[73]  M. Panczyk.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. , 2014, World journal of gastroenterology.

[74]  N. Koide,et al.  Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes , 2007, Scandinavian journal of gastroenterology.

[75]  A. Escargueil,et al.  Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor , 2014, Oncotarget.

[76]  Marc Peeters,et al.  Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. , 2014, The Lancet. Oncology.

[77]  H. Nielsen,et al.  Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort , 2013, PloS one.

[78]  A. Bardelli,et al.  TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells , 2014, Clinical Cancer Research.

[79]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[80]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[81]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[82]  H. McLeod,et al.  Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. , 1996, British Journal of Cancer.

[83]  I. Nagtegaal,et al.  Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. , 2009, European journal of cancer.

[84]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Tae Won Kim,et al.  Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). , 2015 .

[86]  J. Lindebjerg,et al.  DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. , 2007, International journal of oncology.

[87]  N. Meropol,et al.  UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  Jeffrey S. Morris,et al.  The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer , 2013, PloS one.

[89]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[90]  R. Greil,et al.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[92]  X. Qian,et al.  Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine‐based chemotherapy: Evidence from 24 studies , 2008, International journal of cancer.

[93]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  G Milano,et al.  Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  M. Esteller,et al.  Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer , 2013, Journal of the National Cancer Institute.

[96]  A Messori,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[97]  Emmanuel Mitry,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[98]  D. Shin,et al.  S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. , 2012, The Lancet. Oncology.

[99]  P. Hoff,et al.  Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy , 2013, British Journal of Cancer.

[100]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[102]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[103]  R. Kim,et al.  Genetic variability in CYP3A5 and its possible consequences. , 2004, Pharmacogenomics.

[104]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[105]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[106]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  G. Fontanini,et al.  Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[109]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[110]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[111]  N. Sugimoto,et al.  TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2012, The Lancet. Oncology.

[112]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[113]  A. Bardelli,et al.  Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.

[114]  G. Botti,et al.  The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies , 2013, Cancer biology & therapy.

[115]  M. Baiget,et al.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[116]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[117]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  M. Villalona-Calero,et al.  Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[120]  D. Kerr,et al.  Chemotherapy for colorectal cancer , 2000, Journal of the Royal Society of Medicine.

[121]  I. Hyodo,et al.  Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.

[122]  K. Kinzler,et al.  Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.

[123]  Cizhong Jiang,et al.  Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. , 2014, Cancer letters.

[124]  T. Ishikawa,et al.  Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. , 1993, The Journal of biological chemistry.

[125]  M. Salto‐Tellez,et al.  Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[126]  M. Baiget,et al.  Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? , 2006, Cancer Chemotherapy and Pharmacology.

[127]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[128]  E. Mitchell.  Targeted therapy for metastatic colorectal cancer: role of aflibercept. , 2013, Clinical colorectal cancer.

[129]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  S. Hector,et al.  In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.

[132]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[133]  L. Kèlland,et al.  New platinum antitumor complexes. , 1993, Critical reviews in oncology/hematology.

[134]  Kenneth M. Yamada,et al.  Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. , 2001, Journal of cell science.

[135]  J. P. Saini,et al.  Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[136]  F. Russo,et al.  EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. , 1998, Acta oncologica.

[137]  G. Meersma,et al.  Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. , 1992, Cancer research.

[138]  M. Meyers,et al.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.

[139]  K. Isshi,et al.  Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU , 2002, International Journal of Clinical Oncology.

[140]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[142]  Dian-jun Ye,et al.  Research development of the relationship between thymidine phosphorylase expression and colorectal carcinoma , 2013, Cancer biology & medicine.

[143]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[144]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  Marc Peeters,et al.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.

[146]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[147]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[148]  R. Greil,et al.  Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. , 2014, World journal of gastroenterology.

[149]  C. Carlomagno,et al.  Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. , 2014, World journal of gastroenterology.

[150]  A. Ullrich,et al.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.

[151]  M. Tzardi,et al.  Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients , 2011, PloS one.

[152]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[153]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  M. Hidalgo,et al.  Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer , 2016, American journal of clinical oncology.

[155]  M. Kusano,et al.  Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[156]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[157]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  G. Milano,et al.  Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. , 2010, British journal of clinical pharmacology.

[159]  Sanjay Goel,et al.  PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.

[160]  J. Parker.  Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein , 2003 .

[161]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[162]  Menghong Sun,et al.  Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer , 2013, Medical Oncology.

[163]  K. Jung,et al.  S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis , 2013, British Journal of Cancer.

[164]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[165]  R. Labianca,et al.  Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[166]  Masahiro Fukuoka,et al.  Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. , 2002, Lung cancer.

[167]  S. Aebi,et al.  The role of DNA mismatch repair in drug resistance. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[168]  L. Ellis,et al.  Intracrine Vascular Endothelial Growth Factor Signaling in Survival and Chemoresistance of Human Colorectal Cancer Cells , 2010, Oncogene.

[169]  B. Gustavsson,et al.  Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer , 2014, BMC Clinical Pathology.

[170]  Y. Sakamoto,et al.  Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer , 2012, British Journal of Cancer.

[171]  H. Sasaki,et al.  Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. , 2007, Surgery.

[172]  T. Fleming,et al.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[174]  J. Mariadason,et al.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. , 2012, Clinical colorectal cancer.

[175]  E. Raymond,et al.  Cellular and molecular pharmacology of oxaliplatin. , 2002, Molecular cancer therapeutics.

[176]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[177]  Martin R. Johnson,et al.  Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells , 2001, Cancer Gene Therapy.

[178]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[179]  Duan Liu,et al.  Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. , 2011, Pharmacogenomics.

[180]  L. Johnson,et al.  Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. , 1985, Molecular pharmacology.

[181]  J. Willson,et al.  A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. , 2007, Cancer research.

[182]  A. Matakidou,et al.  Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[184]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[185]  D. Ribatti.  The discovery of the placental growth factor and its role in angiogenesis: a historical review , 2008, Angiogenesis.

[186]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[187]  Mef Nilbert,et al.  The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.

[188]  Tanja Sušec,et al.  Historical Review , 1917, Acta Cytologica.

[189]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  P. Johnston,et al.  Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. , 1993, Molecular pharmacology.

[191]  R. Moir,et al.  Role of uridine phosphorylase in the anabolism of 5-fluorouracil. , 1985, Biochemical pharmacology.

[192]  A. Harłozińska,et al.  Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas , 2000, Tumor Biology.

[193]  P. Houghton,et al.  Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. , 1983, European journal of cancer & clinical oncology.

[194]  S. Andreola,et al.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[195]  P. Johnston,et al.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.

[196]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[197]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.